Chest
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mulshine, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mulshine, J. L.
(Chest. 1999;116:493S-496S.)
© 1999 American College of Chest Physicians

Reducing Lung Cancer Risk*

Early Detection

James L. Mulshine, MD

* From the Intervention Section, Department of Cell and Cancer Biology, Medicine Branch, Division of Clinical Science, National Cancer Institute, National Institutes of Health, Bethesda, MD.

Correspondence to: James Mulshine, MD, National Cancer Institute, Bldg 10, Rm 12N226, NIH Clinical Center, Bethesda, MD 20892-1906; e-mail: mulshinej{at}bprb.nci.nih.gov

Strategies for the early detection of lung cancer are being investigated in an attempt to improve the poor prognosis associated with the disease. Such approaches, which include the identification of biomarkers for preclinical disease, must be integrated into multimodal cancer prevention strategies. Recent investigations have identified potential markers of early disease, including heterogeneous nuclear ribonucleoprotein, although the use of multiple markers may be required to provide the sensitivity and specificity necessary for mass screening. Early detection necessitates the development of effective chemoprevention strategies for the airway-confined phase of lung cancer. Current research efforts explore the utility of direct drug delivery, such as with the use of aerosolized delivery of retinoids, to maximize delivery of the active agent to the site of early lung cancer while avoiding systemic adverse effects.




This article has been cited by other articles:


Home page
 Genome ResHome page
M. Xiong, X. Fang, and J. Zhao
Biomarker Identification by Feature Wrappers
Genome Res., November 1, 2001; 11(11): 1878 - 1887.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Sharma, D. White, A. R. Imondi, M. E. Placke, D. M. Vail, and M. G. Kris
Development of Inhalational Agents for Oncologic Use
J. Clin. Oncol., March 15, 2001; 19(6): 1839 - 1847.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. R. Hirsch, W. A. Franklin, A. F. Gazdar, and P. A. Bunn Jr.
Early Detection of Lung Cancer: Clinical Perspectives of Recent Advances in Biology and Radiology
Clin. Cancer Res., January 1, 2001; 7(1): 5 - 22.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American College of Chest Physicians.